Skip to main content
SpringerLink
Log in
Book cover

Lymphohaematopoietic Growth Factors in Cancer Therapy pp 57–77Cite as

Interleukin 2: Clinical Aspects

  • Conference paper

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

Abstract

Interleukin 2 (IL2) has established im-munotherapy as the fourth modality of cancer treatment. The clinical exploitation was greatly accelerated by the more widespread availability of the recombinant (rlL2) material. The design of the first clinical protocols with rlL2 was based on investigations in murine sarcomas of variable immunogenicity at the National Cancer Institute, Bethesda. Interest was stimulated in particular by 3 reports of objective responses in patients with refractory cancers treated with rIL2 with and without lymphokine activated killer (LAK) cells, [1-3]. The chronology of these early NCI and subsequent studies from other centres is shown in Table 1 with appropriate references, [4-51]. Since then, there has been a plethora of clinical and allied reports concerning rlL2. This review will briefly summarise some of the clinical aspects of rIL2 therapy when used alone (without LAK cells) and recent combinations of rIL2 with other materials.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Rosenburg SA, Lotze MT, Muui LM et al: Special report — Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985 (313):1485–1492.

    Article  Google Scholar 

  2. Rosenberg SA, Lotze MT, Muul LM et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987 (316):889–897.

    Article  PubMed  CAS  Google Scholar 

  3. West WH, Tauer KW, Yannelli JR et al: Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987 (316):898–905.

    Article  PubMed  CAS  Google Scholar 

  4. Lotze MT, Line BR, Mathisen DJ and Rosenberg S A: The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): Implications for the adoptive immunotherapy of tumors. J Immunol 1980 (125):1487–1493.

    PubMed  CAS  Google Scholar 

  5. Mazumder A, Grimm EA, Rosenberg SA: Lysis of fresh human solid tumor cells by autologous lymphocytes activated in vitro by allosensitization. Cancer Immunol Immunother 1983 (15):1–10.

    Article  PubMed  CAS  Google Scholar 

  6. Rosenberg SA: Immunotherapy of cancer by the systemic administration of lymphoid cells plus interleukin-2. J Biol Resp Mod 1985 (3):501–511.

    Google Scholar 

  7. Pizza G, Severini G, Menniti D et al: Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary report. Int J Cancer 1984 (34):359–367.

    Article  PubMed  CAS  Google Scholar 

  8. Lotze MT, Matory YL, Ettinghausen SE et al: In vivo administration of purified human interleukin 2. II. Half-life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J Immunol 1985 (135):2865–2875.

    PubMed  CAS  Google Scholar 

  9. Atkins MB, Gould JA, Allegretta M et al: Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease. Clin Oncol 1986 (4):1380–1391.

    CAS  Google Scholar 

  10. Lotze MT, Chang AE, Seipp CA et al: High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. JAMA 1986 (256):3117–3124.

    Article  PubMed  CAS  Google Scholar 

  11. Lotze MT, Custer MC and Rosenberg SA: Intraperitoneal administration of interleukin-2 in patients with cancer. Arch Surg 1986 (121):1373–1379.

    PubMed  CAS  Google Scholar 

  12. Thompson JA, Lee DJ, Cox WW et al: Recombinant interleukin 2 toxicity, pharmacokinetics and immunomodulatory effects in a phase I trial. Cancer Res 1987 (47):4202–4207.

    PubMed  CAS  Google Scholar 

  13. Wang J, Walle A, Gordon B et al: Adoptive immunotherapy for stage IV renal cell carcinoma: a novel protocol utilizing periodate and interleukin 2 activated autologous leukocytes and continuous infusions of low dose interleukin 2. Am J Med 1987 (83):1016–1023.

    Article  PubMed  CAS  Google Scholar 

  14. Yasumoto K, Miyazaki K, Nagashima A et al: Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer. Cancer Res 1987 (47):2184–2187.

    PubMed  CAS  Google Scholar 

  15. Marolda R, Belli F, Prada A et al: A phase I study of recombinant interleukin 2 in melanoma patients. Toxicity and clinical effects. Tumori 1987 (73):575–584.

    PubMed  CAS  Google Scholar 

  16. Merguerian PA, Donahue L and Cockett ATK: Intraluminal interleukin 2 and Bacillus Calmette-Guerin for treatment of bladder cancer: A preliminary report. J Urol 1987 (137):216–219.

    PubMed  CAS  Google Scholar 

  17. Rosenberg SA: The development of new immunotherapies for the treatment of cancer using interleukin-2. Ann Surg 1988 (208):121–135.

    Article  PubMed  CAS  Google Scholar 

  18. Sondel PM, Kohler PC, Hank JA et al: Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer. Cancer Res 1988 (48):2561–2567.

    PubMed  CAS  Google Scholar 

  19. Fisher Rl, Coltman CA, Doroshow JH et al: Metastatic renal cancer treated with interleukin-2 and lymphokine activated killer cells. Ann Int Med 1988 (108):518–523.

    PubMed  CAS  Google Scholar 

  20. Thompson JA, Lee DJ, Lindgren CG et al: Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. J Clin Oncol 1988 (6):669–678.

    PubMed  CAS  Google Scholar 

  21. Mitchell MS, Kempf RA, Harel W et al: Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 disseminated melanoma. J Clin Oncol 1988 (6):409–424.

    PubMed  CAS  Google Scholar 

  22. Sosman JA, Kohler PC, Hank JA et al: Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule and additon of indomethacin. JNCI 1988 (80):1451–1461.

    PubMed  CAS  Google Scholar 

  23. Richards JM, Barker E, Latta J et al: Phase I study of weekly 24-hour infusions of recombinant human interleukin 2. JNCI 1988 (80):1325–1328.

    PubMed  CAS  Google Scholar 

  24. Pizza G, Viza D, De Vinci C et al: Intra-lymphatic administration of interleukin-2 (IL-2) in cancer patients: A pilot study. Lymphokine Res 1988 (7):45–48.

    PubMed  CAS  Google Scholar 

  25. Schoof DD, Gramolini BA, Davidson DL et al: Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res 1988 (48):5007–5010.

    PubMed  CAS  Google Scholar 

  26. Krigel RL, Padavic-Shaller KA, Rudolph AR et al: A phase I study of recombinant interleukin 2 plus recombinant B-interferon. Cancer Res 1988 48):3875–3881.

    PubMed  CAS  Google Scholar 

  27. Javadpour N and Lalehzarian M: A phase Ml study of high-dose recombinant human interleukin-2 in disseminated renal-cell carcinoma. Semin Surg Oncol 1988 (4):207–209.

    Article  PubMed  CAS  Google Scholar 

  28. Yoshida S, Tanaka R, Takai N and Ono K: Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumours. Cancer Res 1988 (48):5011–5016.

    PubMed  CAS  Google Scholar 

  29. Cortesina G, De Stefani A, Giovarelli M et al: Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically. Cancer 1988 (62):2482–2485.

    Article  PubMed  CAS  Google Scholar 

  30. Chapman PB, Kolitz JE, Hakes TB et al: A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma. Investig New Drugs 1988 (6):179–188.

    CAS  Google Scholar 

  31. Merchant RE, Grant AJ, Merchant LH et al: Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2. Cancer 1988 (62):665–671.

    Article  PubMed  CAS  Google Scholar 

  32. Onishi S, Saibara T, Fujikawa M et al: Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma. Hepatology 1989 (10):349–353.

    Article  PubMed  CAS  Google Scholar 

  33. Nasr S, McKolanis J, Pais R et al: A phase I study of interleukin-2 in children with cancer and evaluation of clinical and immunologic status during therapy. A Pediatric Oncology Group Study. Cancer 1989 (64):783–788.

    Article  PubMed  CAS  Google Scholar 

  34. Stahel RA, Sculier JP, Jost LM et al: Tolerance and effectiveness of recombinant interleukin-2 (r-met Hu IL-2 [ala-125]) and lymphokine-activated killer cells in patients with metastatic solid tumors. Eur J Cancer Clin Oncol 1989 (25):965–972.

    Article  PubMed  CAS  Google Scholar 

  35. Marumo K, Muraki J, Ueno M et al: Immunologic study of human recombinant interleukin-2 (low-dose) in patients with advanced renal cell carcinoma. Urology 1989 (33):219–225.

    Article  PubMed  CAS  Google Scholar 

  36. Allison MAK, Jones SE and McGuffey P: Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia and selected solid tumors. J Clin Oncol 1989 (7):75–80.

    PubMed  CAS  Google Scholar 

  37. Paolozzi F, Zamkoff K, Doyle M et al: Phase I trial of recombinant interleukin-2 and recombinant B-interferon in refractory neoplastic disease. J Biol Resp Mod 1989 (8):122–139.

    CAS  Google Scholar 

  38. Rosenberg SA, Lotze MT, Yang JC et al: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989 (210):442–474.

    Article  Google Scholar 

  39. Thatcher N, Dazzi H, Johnson RJ et al: Recombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for advanced malignant melanoma. A phase I and II study. Br J Cancer 1989 (60):770–774.

    Article  PubMed  CAS  Google Scholar 

  40. Sznol M, Dutcher JP, Atkins MB et al: Review of interleukin-2 alone and interleukin 2/ LAK clinical trials in metastatic malignant melanoma. Cancer Treat Rev 1989 (16 Suppl A):29–38.

    Article  PubMed  Google Scholar 

  41. Stoter G, Shiloni E, Aamdal S et al: Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentric phase II study. Eur J Cancer Clin Oncol 1989 (25 Suppl 3):S41–S43.

    PubMed  Google Scholar 

  42. Flaherty L: The combination of recombinant interleukin-2 and dacarbazine (DTIC) in metastatic malignant melanoma. Cancer Treat Rev 1989 (16 Suppl A):65–66.

    Article  Google Scholar 

  43. Lindermann A, Hoeffken K, Schmidt et al: A multicenter trial of interleukin-2 and low-dose cyclophosphamide in highly chemotherapy-resistant malignancies. Cancer Treat Rev 1989 (16 Suppl A):53–57.

    Article  Google Scholar 

  44. Paciucci PA, Holland JF, Ryder JS et al: Immunotherapy with interleukin-2 by constant infusion with and without adoptive cell transfer and with weekly doxorubicin. Cancer Treat Rev 1989 (16 Suppl A):67–81.

    Article  PubMed  Google Scholar 

  45. West WH: Continuous infusion recombinant interleukin-2 (rIL-2) in adoptive cellular therapy of renal carcinoma and other malignancies. Cancer Treat Rev 1989 (16 Suppl A):83–89.

    Article  PubMed  Google Scholar 

  46. Negrier S, Philip T, Stoter et al: Interleukin-2 with and without LAK cells in metastatic renal cell carcinoma: A report of a European multicentre study. Eur J Cancer Clin Oncol 1989 (25 Suppl 3):S21–S28.

    PubMed  Google Scholar 

  47. Panici PB, Scambia G, Greggi S et al: Recombinant interleukin-2 continuous infusion in ovarian cancer patients with minimal residual disease at second-look. Cancer Treat Rev 1989 (16 Suppl. A):123–127.

    Article  Google Scholar 

  48. Rosenberg SA, Lotze MT, Yang JC et al: Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989 (7):1863–1874.

    PubMed  CAS  Google Scholar 

  49. Lee KH, Talpaz M, Rothbeg JM et al: Concomitant administration of recombinant human interleukin-2 and recombinant alpha-2A in cancer patients: A phase I Study. J Clin Oncol 1989 (7):1726–1732.

    PubMed  CAS  Google Scholar 

  50. Thatcher N, Dazzi H, Mellor M et al: Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: a phase II study. Br J Cancer 1990 (61):618–621.

    Article  PubMed  CAS  Google Scholar 

  51. Bukowski RM, Goodman P, Crawford ED et al: Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: A Southwest Oncology Group study. JNCI 1990 (82):143–146.

    PubMed  CAS  Google Scholar 

  52. Sondel PM, Hank JA, Kohler PC et al: The cellular immunotherapy of cancer: current and potential uses of interleukin-2. Crit Rev Oncol/Haematol 1989 (9):125–147.

    Article  CAS  Google Scholar 

  53. Sarna GP, Figlin RA, Pertcheck, M et al: Systemic administration of recombinant methionyl human interleukin-2 (Ala 125) to cancer patients: clinical results. J Biol Res Mod 1989 (8):16–24.

    CAS  Google Scholar 

  54. Allegretta M, Atkins MB, Dempsey RA et al: The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2). J Clin Immunol 1986 (6):481–489.

    Article  PubMed  CAS  Google Scholar 

  55. Sano T, Saijo N, Sasaki Y et al: Three schedules of recombinant human interleukin-2 in the treatment of malignancy: side effects and immunologic effects in relation to serum level. Jpn J Cancer Res 1988 (79):131–143.

    Article  PubMed  CAS  Google Scholar 

  56. Hank JA, Kohler PC, Weil-Hillman G et al: In vivo induction of the lymphokine-activated killer phenomenon: Interleukin-2 — dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin-2. Cancer Res 1988 (48):1965–1971.

    PubMed  CAS  Google Scholar 

  57. Creekmore P, Harris JE, Ellis TM et al: A Phase I clinical trial of recombinant interleukin-2 by periodic 24 hour intravenous infusions. J Clin Oncol 1989 (7):276–284.

    PubMed  CAS  Google Scholar 

  58. Ghosh AK, Dazzi H, Thatcher N and Moor M: Lack of correlation between peripheral blood lymphokine-activated killer (LAK) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2. Int J Cancer (43):410–414.

    Google Scholar 

  59. McMannis JD, Fisher RI, Creekmore SP et al: in vivo effects of Recombinant IL-2. I. Isolation of circulating Leu-19+ Lymphokine-Activated Killer effector cells from cancer patients receiving recombinant IL-2. J Immunology 1988 (140):1335–1340.

    CAS  Google Scholar 

  60. Gambacorti-Passerini C, Rivoltini L, Radrizzani M et al: Differences between In vivo and In vitro activation of cancer patient lymphocytes by recombinant interleukin 2: Possible role for Lymphokine-Activated Killer cell infusion in the In vitro — induced activation. Cancer Res 1989 (49):5230–5234.

    PubMed  CAS  Google Scholar 

  61. Walewski J, Paietta E, Dutcher J and Wiernik PH: Evaluation of natural killer and lymphokine-activated killer (LAK) cell activity in vivo in patients treated with high-dose interleukin-2 and adoptive transfer of autologous LAK cells. J Cancer Res Clin Oncol 1989 (115):170–174.

    Article  PubMed  CAS  Google Scholar 

  62. Boldt DH, Mills BJ, Gemlo BT et al: Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans. Cancer Res 1988 (48):4409–4416.

    PubMed  CAS  Google Scholar 

  63. Thompson JA, Lee DJ, Lindgren CG, et al: Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells. Cancer Res 1989 (49):235–240.

    PubMed  CAS  Google Scholar 

  64. Phillips JH and Lanier LL et al: Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolosis. J Exp Med 1986 (164):814–825.

    Article  PubMed  CAS  Google Scholar 

  65. Gemlo BT, Palladino MA, Jaffe HS et al: Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res 1988 (48):5864–5867.

    PubMed  CAS  Google Scholar 

  66. Heslop HE, Gottlieb DJ, Bianchi AC et al: In vivo induction of gamma interferon and tumour necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous transplantation. Blood 1989 (4):1374–1380.

    Google Scholar 

  67. Parkinson D: Interleukin-2 in cancer therapy. Semin Oncol 1988 (6 Suppl 6):10–26.

    Google Scholar 

  68. De Fries RU and Golub SH: Characteristics and mechanism of IFN-induced protection of human tumour cells from lysis by lymphokine-activated killer cells. J Immunol 1988 (10):3686–3693.

    Google Scholar 

  69. Lee RE, Lotze MT, Skibber JM et al: Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol 1989 (7):7–20.

    PubMed  CAS  Google Scholar 

  70. Cotran RS, Pober JS, Gimbrone MA et al: Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome. J Immunol 1987 (139):1883–1888.

    Google Scholar 

  71. Mier JW, Brandon EP, Libby P et al: Activated endothelial cells resist lymphokine-activated killer cell-mediated injury. Possible role of induced cytokines in limiting capilliary leak during IL-2 therapy. J Immunol 1989 (143):2407–2414.

    PubMed  CAS  Google Scholar 

  72. Krigel RL, Padavic-Shaller KA, Rudolph AR et al: Exacerbation of epidemic Kaposi’s sarcoma with a combination of interleukin-2 and beta-interferon: Results of a phase 2 study. J Biol Response Mod 1989 (8):359–365.

    PubMed  CAS  Google Scholar 

  73. Hamblin TJ: Interleukin-2. Side effects are acceptable. Br Med J 1990 (300):275–276.

    Article  CAS  Google Scholar 

  74. Herberman RB: Interleukin-2 therapy of human cancer: Potential benefits versus toxicity. J Clin Oncol 1989 (7):1–4.

    PubMed  CAS  Google Scholar 

  75. Eberlein TJ, Schoof DD, Michie HR et al: Ibuprofen causes reduced toxic effects of Interleukin 2 administration in patients with metastatic cancer. Arch Surg 1989 (124):542–547.

    PubMed  CAS  Google Scholar 

  76. Vetto JT, Papa MZ, Lotze MT et al: Reduction of toxicity of interleukin-2 and Lymphokine-Activated Killer cells in humans by the administration of corticosteroids. J Clin Oncol 1987 (5):496–503.

    PubMed  CAS  Google Scholar 

  77. Belldegrun A, Webb DE, Austin HA et al: Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: Effect of pre-therapy nephrectomy. Urology 1989 (141):499–503.

    CAS  Google Scholar 

  78. Javadpour N and Lalehzarian M: Role of interleukin 2 alone in disseminated renal cell carcinoma: An update. Prog Clin Biol Res 1989 (303):671–679.

    PubMed  CAS  Google Scholar 

  79. Cohen PJ, Lotze MT, Roberts JR et al: The immunopathology of sequential tumour biopsies in patients treated with interleukin-2: Correlation of response with T-cell infiltration and HLA-DR expression. Am J Pathology 1987 (129):208–216.

    CAS  Google Scholar 

  80. Atkins MB, Mier JW, Parkinson DR et al: Hypothyroidism after treatment with interleukin-2 and Lymphokine-Activated Killer cells. N Engl J Med 1988 (314):1557–1563.

    Article  Google Scholar 

  81. Kohler PC, Hank JA, Moore KH et al: Phase I clinical trial of recombinant interleukin-2: A comparison of bolus and continuous intravenous infusion. Cancer Investig 1989 (7):213–223.

    Article  CAS  Google Scholar 

  82. Kolitz JE, Weite K, Wong GY et al: Expansion of activated T-Lymphocytes in patients treated with recombinant interleukin 2. J Biol Resp Mod 1987 (6):412–429.

    CAS  Google Scholar 

  83. Kay NE, Oken MM, Mazza JJ, Bradley EC: Evidence for tumor reduction in refractory or relapsed B-CLL patients with infusional interleukin 2. Nouv Rev Fr Hematol 1988 (30):475–478.

    PubMed  CAS  Google Scholar 

  84. Roth AD and Kirkwood JM: New clinical trials with interleukin-2: rationale for regional administration. Nat Immun Cell Growth Regul 1989 (8):153–164.

    PubMed  CAS  Google Scholar 

  85. Pizza G, Berton F, Casanova S et al: Interleukin 2 in the treatment of infiltrating bladder cancer. J Exp Path 1987 (3):525–531.

    CAS  Google Scholar 

  86. Huland E and Huland H: Local continuous high dose interleukin 2: A new therapeutic model for the treatment of advanced bladder carcinoma. Cancer Res 1989 (49):5469–5474.

    PubMed  CAS  Google Scholar 

  87. Thatcher N, Taylor P, Carroll KB et al: Interleukin 2 in malignant pleural mesothelioma (and adenocarcinoma of the lung). The use of intrapleural and continuous intravenous infusions: preliminary results. Cancer Treat Rev 1989 (16 Suppl A):161–162.

    Article  PubMed  Google Scholar 

  88. Kolitz JE, Wong GY, Weite K et al: Phase I trial of recombinant Interleukin 2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2. J Biol Resp Mod 1988 (7):457–472.

    CAS  Google Scholar 

  89. Stoter G, Shiloni E, Aamdal S et al: Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II study. Eur J Cancer Clin Oncol 1989 (25 Suppl 3):S41–S43.

    PubMed  Google Scholar 

  90. Shiloni E, Pouillart P, Janssens J et al: Sequential dacarbazine chemotherapy followed by recombinant interleukin 2 in metastatic melanoma. A pilot multicentre phase Ml study. Eur J Cancer Clin Oncol 1989 (25 Suppl 3):S45–S49.

    PubMed  Google Scholar 

  91. Wagstaff J, Vermerken JB, Schwartsmann G et al: A progress report of a phase I study of Interferon gamma and interleukin 2 and some comments on the mechanism of the toxicity due to Interleukin 2. Cancer Treat Rev 1989 (16 Suppl A):105–109.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Research Campaign, Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester, M20 9BX, UK

    N. Thatcher

Authors
  1. N. Thatcher
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abteilung Innere Medizin I, Klinikum der Albert-Ludwigs-Universität Hugstetter, Straße 55, 7800, Freiburg, Federal Republic of Germany

    Roland Mertelsmann

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Spinger-Verlag Berlin Heidelberg

About this paper

Cite this paper

Thatcher, N. (1990). Interleukin 2: Clinical Aspects. In: Mertelsmann, R. (eds) Lymphohaematopoietic Growth Factors in Cancer Therapy. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76037-2_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-76037-2_7

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-76039-6

  • Online ISBN: 978-3-642-76037-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation